Adaptive Biotechnologies
JP Morgan Healthcare Conference, Day 2: CareDx, Thermo Fisher, BillionToOne, Adaptive Biotech, More
Highlights from the second day included BillionToOne's 2024 revenue spike and CareDx's plan to expand indications for its transplant tests.
NeoGenomics, Adaptive Biotech Partner to Offer Combined Blood Cancer Testing
Doctors ordering NeoGenomics Compass test packages will have the option of including Adaptive's ClonoSeq minimal residual disease assay.
In Brief This Week: Adaptive Biotechnologies, Qiagen, OraSure Technologies, Hologic, More
News items for the week of Jan. 6, 2025.
Adaptive Biotechnologies Revenues Rise 22 Percent in Q3
The firm's MRD revenue rose 52 percent year over year, while immune medicine revenue declined 32 percent.
Adaptive Biotechnologies Test Receives Expanded Medicare Coverage for Mantle Cell Lymphoma
The firm's blood-based ClonoSeq test can be used to assess response to treatment, understand prognosis, and monitor patients to detect molecular recurrence.